Using the clinical symptoms and signs of GCA as a guide (often recommended by rheumatologists) is a dangerous practice to prevent blindness.[59] In my study, I found that there is a risk of further visual loss during the first 5 days of the start of high-dose steroid therapy;[60] after that, no one in my study lost any further vision when steroid therapy tapering was guided by the ESR and CRP levels. Here, CRP is linked to temporal arteritis.